AdAlta (ASX:1AD)
AdAlta develops antibody-like drugs called ‘i-bodies’ with the same target specificity and affinity as monoclonal antibodies, but about 90% smaller. AdAlta’s first clinical product from its platform will be indicated for the treatment of Idiopathic Pulmonary Fibrosis.
13/09/2016 Smaller, smarter antibody-like drugs
20/02/2017 i-bodies continue to make progress